Worth Watching: LeMaitre Vascular Inc Surges to 52-Week High, Is Now Top Performer

Worth Watching: LeMaitre Vascular Inc Surges to 52 Week High, Is Now Top Performer

The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) hit a new 52-week high and has $59.06 target or 139.00% above today’s $24.71 share price. The 6 months bullish chart indicates low risk for the $473.79M company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $59.06 price target is reached, the company will be worth $658.57M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 201,519 shares traded hands or 26.21% up from the average. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 50.35% since April 15, 2016 and is uptrending. It has outperformed by 45.72% the S&P500.

LeMaitre Vascular Inc (NASDAQ:LMAT) Ratings Coverage

Out of 9 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. LeMaitre Vascular has been the topic of 22 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Buy” rating by Dougherty & Company on Monday, December 7. The firm has “Outperform” rating by Cowen & Co given on Thursday, April 21. The rating was initiated by Sidoti on Wednesday, January 20 with “Neutral”. The stock has “Buy” rating given by Stifel Nicolaus on Friday, December 4. The firm earned “Mkt Perform” rating on Thursday, September 10 by Barrington Research. The firm has “Neutral” rating given on Thursday, September 22 by Sidoti. Roth Capital maintained the shares of LMAT in a report on Tuesday, May 3 with “Buy” rating. TH Capital maintained LeMaitre Vascular Inc (NASDAQ:LMAT) rating on Monday, December 7. TH Capital has “Buy” rating and $18 price target. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Outperform” rating by Barrington Research on Thursday, February 25. The firm earned “Buy” rating on Tuesday, May 3 by Canaccord Genuity.

According to Zacks Investment Research, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.”

Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.79, from 2.03 in 2016Q1. The ratio dropped, as 6 funds sold all LeMaitre Vascular Inc shares owned while 31 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 10.35 million shares or 1.88% more from 10.16 million shares in 2016Q1.
Wedge Cap Mngmt L Lp Nc accumulated 0.01% or 52,000 shares. Aqr Cap Limited Liability Company has 109,281 shares for 0% of their US portfolio. Moreover, First Light Asset has 2.55% invested in LeMaitre Vascular Inc (NASDAQ:LMAT) for 385,562 shares. Blackrock Institutional Trust Na accumulated 0% or 259,143 shares. Moreover, Diam Limited has 0% invested in LeMaitre Vascular Inc (NASDAQ:LMAT) for 8,740 shares. Tower (Trc) has 0% invested in the company for 1,200 shares. Moreover, Columbia Wanger Asset Limited has 0.09% invested in LeMaitre Vascular Inc (NASDAQ:LMAT) for 559,839 shares. Utd Services Automobile Association holds 0.01% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 107,501 shares. The Illinois-based Driehaus Mgmt Ltd Co has invested 0.21% in LeMaitre Vascular Inc (NASDAQ:LMAT). Financial Bank Of Ny Mellon accumulated 0% or 81,013 shares. The Pennsylvania-based Tfs Lc has invested 0.22% in LeMaitre Vascular Inc (NASDAQ:LMAT). Analytic Investors Limited Com last reported 0.02% of its portfolio in the stock. Allianz Asset Ag holds 0% or 336,656 shares in its portfolio. Credit Suisse Ag owns 36,841 shares or 0% of their US portfolio. First Quadrant L P Ca reported 5,600 shares or 0% of all its holdings.

Insider Transactions: Since May 20, 2016, the stock had 0 buys, and 24 sales for $7.29 million net activity. LeMaitre Cornelia W had sold 22,500 shares worth $390,560. LeMaitre George W sold $1.10 million worth of stock. On Tuesday, May 24 the insider Kamke Trent G sold $23,248. 11,905 shares were sold by Gebauer Peter R, worth $182,373. Roberts David B also sold $135,829 worth of LeMaitre Vascular Inc (NASDAQ:LMAT) shares. Jasinski Lawrence J sold $132,001 worth of stock.

Another recent and important LeMaitre Vascular Inc (NASDAQ:LMAT) news was published by Nasdaq.com which published an article titled: “LeMaitre Vascular, Inc. (LMAT) Ex-Dividend Date Scheduled for November 17, 2016” on November 16, 2016.

LMAT Company Profile

LeMaitre Vascular, Inc., incorporated on June 15, 1998, is a well-known provider of medical devices for the treatment of peripheral vascular disease. The Firm and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. The Company’s portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. The Company’s principal product offerings are sold across the world, primarily in the United States, Europe, Asia and the Pacific Rim. The Company’s subsidiaries include LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment